Research

Researchers from UCSF’s Department of Radiology & Biomedical Imaging were recently awarded a $3.93 million Translational Team Science Award.

A team of investigators from the Abuabara Lab at UC San Francisco, UCSF Radiology and the University of Arizona reviewed available literature on skin sodium to investigate its connection to total body sodium and to immunity.

There have been growing national efforts to diversify the radiology workforce, but are those efforts having an impact? Xiao Wu, MD, a resident at the UC San Francisco Department of Radiology and Biomedical Imaging, investigated the question and shared her findings in a journal article and a podcast.

Kondapa Naidu Bobba, PhD, is first author of "Evaluation of 134Ce/134La as a PET Imaging Theranostic Pair For 225Ac -Radiotherapeutics," a Journal of Nuclear Medicine (JNM) article published May 18 that discusses the development of a robust radiolabeling methodology and applied optimized method for utilizing prostate cancer targeting agents PSMA-617 and antibody YS5.

2023 Workshop HMTRC celebrated its 11^th year as a center, and its annual Workshop continues to have a national and global impact on advancing hyperpolarized carbon-13  MR molecular imaging technology.

Melanie Morrison, PhD, is an assistant professor in residence in the Department of Radiology and Biomedical Imaging at UCSF, and a core member of the UCSF-UC Berkeley Joint PhD Program in Bioengineering. 

Parkinson's Disease is a chronic and progressive movement disorder that affects around 10 million people worldwide. Dr. Tosun-Turgut provides an overview of new research into and treatments for PD.

https://cdmrp.health.mil/funding/pcrp.aspxAnil Bidkar, PhD, has received the Department of Defense (DoD) Prostate Cancer Research Program (PCRP) Early Investigator Research Award.

Beyond PSMA: CD46 Targeted 225Ac Alpha Particle Radioimmunotherapy for Prostate Cancer

In a recent interview reflecting on ADNI’s significance in advancing Alzheimer’s research, Dr. Weiner observed that a major challenge for all clinical trials is that the trial participants do not fully represent the populations of people who need treatment.